Mostrar el registro sencillo del ítem
dc.contributor.author
Mojica, María F.
dc.contributor.author
De La Cadena, Elsa
dc.contributor.author
Ríos, Rafael
dc.contributor.author
García Betancur, Juan Carlos
dc.contributor.author
Díaz, Lorena
dc.contributor.author
Reyes, Jinnethe
dc.contributor.author
Hernández Gómez, Cristhian
dc.contributor.author
Radice, Marcela Alejandra
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Gales, Ana C.
dc.contributor.author
Castañeda Méndez, Paulo
dc.contributor.author
Munita, José M.
dc.contributor.author
Pallares, Christian José
dc.contributor.author
Martínez, José R. W.
dc.contributor.author
Villegas, María Virginia
dc.date.available
2023-11-13T12:24:39Z
dc.date.issued
2022-10
dc.identifier.citation
Mojica, María F.; De La Cadena, Elsa; Ríos, Rafael; García Betancur, Juan Carlos; Díaz, Lorena; et al.; Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries; Frontiers Media; Frontiers in Microbiology; 13; 10-2022; 1-8
dc.identifier.uri
http://hdl.handle.net/11336/217847
dc.description.abstract
Objectives: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction of TOL into the clinical practice. Methods: Clinical isolates of P. aeruginosa (n = 504) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to TOL were determined by standard broth microdilution and interpreted according to CLSI breakpoints. Initially, production of carbapenemases in TOL non-susceptible isolates was assessed by Rapidec® followed by qPCR to detect blaKPC, blaNDM-1, blaVIM, and blaIMP. Illumina® WGS was performed for isolates in which non-susceptibility to TOL was not mediated by carbapenemases. Results: A total of 158 (31.3%) isolates were non-susceptible to TOL. In 74 (46.8%) of these isolates, non-susceptibility to TOL was explained by the production of at least one carbapenemase. WGS revealed that some isolates carried ESBLs, mutated blaPDC and ampD, associated with decreased susceptibility to TOL. Conclusion: Substitutions found in PDC and carbapenemase production were the most common presumed mechanisms of resistance to TOL detected in this study. This study shows that epidemiological surveillance is warranted to monitor the emergence of novel mechanisms of resistance to TOL that might compromise its clinical utility.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Frontiers Media
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
ANTIBIOTIC RESISTANCE
dc.subject
CEFTOLOZANE/TAZOBACTAM
dc.subject
LATIN AMERICA
dc.subject
MOLECULAR MECHANISMS
dc.subject
PSEUDOMONAS AERUGINOSA
dc.subject.classification
Otras Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2023-11-10T14:35:20Z
dc.identifier.eissn
1664-302X
dc.journal.volume
13
dc.journal.pagination
1-8
dc.journal.pais
España
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: Mojica, María F.. Case Western Reserve University; Estados Unidos
dc.description.fil
Fil: De La Cadena, Elsa. Universidad El Bosque;
dc.description.fil
Fil: Ríos, Rafael. Universidad El Bosque;
dc.description.fil
Fil: García Betancur, Juan Carlos. Universidad El Bosque;
dc.description.fil
Fil: Díaz, Lorena. Universidad El Bosque;
dc.description.fil
Fil: Reyes, Jinnethe. Universidad El Bosque;
dc.description.fil
Fil: Hernández Gómez, Cristhian. Universidad El Bosque;
dc.description.fil
Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Gales, Ana C.. Universidade Federal de Sao Paulo; Brasil
dc.description.fil
Fil: Castañeda Méndez, Paulo. Fundacion Clinica Medica Sur; México
dc.description.fil
Fil: Munita, José M.. Universidad del Desarrollo; Chile
dc.description.fil
Fil: Pallares, Christian José. Universidad El Bosque;
dc.description.fil
Fil: Martínez, José R. W.. Universidad del Desarrollo; Chile
dc.description.fil
Fil: Villegas, María Virginia. Universidad El Bosque;
dc.journal.title
Frontiers in Microbiology
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fmicb.2022.1035609
Archivos asociados